Quarterly Result12 Aug 2026, 06:21 pm
GKB Ophthalmics Declares Unaudited Q1 FY27 Results
AI Summary
GKB Ophthalmics Ltd. announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors took on record these results during a meeting held on August 12, 2026. The company is challenging a recovery proceeding of ₹8,82,00,856/- by filing a writ petition. Additionally, its wholly-owned subsidiary, GKB Ophthalmics Products FZE, completed the closure of its step-down subsidiary, Prime Ophthalmics Products PTY Limited, due to revenue challenges, resulting in a write-off of AED 1,69,325.58. The legal structure of another subsidiary, Prescription Optical Products LLC, was updated to a Single Owner LLC.
Key Highlights
- Board approved unaudited standalone and consolidated financial results for Q1 FY27.
- Company is challenging a recovery demand of ₹8.82 crore via writ petition.
- Wholly-owned subsidiary closed a step-down subsidiary due to revenue challenges.
- Investment in the closed step-down subsidiary was written off.
- Legal structure of another subsidiary was updated to a Wholly Owned Subsidiary.
Price Impact
More from GKB